Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.
View/ Open
Date
2018-05-22Author
Gao, Q
López-Knowles, E
U Cheang, MC
Morden, J
Ribas, R
Sidhu, K
Evans, D
Martins, V
Dodson, A
Skene, A
Holcombe, C
Mallon, E
Evans, A
Bliss, JM
Robertson, J
Smith, I
Martin, L-A
Dowsett, M
POETIC Trial Management Group and Trialists,
Type
Journal Article
Metadata
Show full item recordAbstract
To investigate the impact of sampling methodology on gene expression data from primary estrogen receptor-positive (ER+) breast cancer biopsies, global gene expression was measured in core-cut biopsies at baseline and surgery from patients randomly assigned to receive either two weeks of presurgical aromatase inhibitor (AI; n = 157) or no presurgical treatment (n = 56). Those genes most markedly altered in the AI group (eg, FOS, DUSP1, RGS1, FOSB) were similarly altered in the no treatment group; some widely investigated genes that were apparently unaffected in the AI group (eg, MYC) were counter-altered in the control group, masking actual AI-dependent changes. In the absence of a control group, these artefactual changes would likely lead to the most affected genes being the erroneous focus of research. The findings are likely relevant to all archival collections of ER+ breast cancer.
Subject
POETIC Trial Management Group and Trialists
Research team
Clinical Trials & Statistics Unit
Genomic Analysis – Clinical Trials
Endocrinology
Language
eng
Date accepted
2018-02-16
License start date
2018-04
Citation
JNCI cancer spectrum, 2018, 2 (2), pp. pky005 - ?
Publisher
OXFORD UNIV PRESS